Global Sleep Disorders Treatment Market Size study & Forecast, by Drug Type (Benzodiazepines, Nonbenzodiazepines, Antidepressants, and Other Drug Types) by Application (Insomnia, Sleep Apnea, Narcolepsy, Circadian disorders, and Other Applications) and Re

Global Sleep Disorders Treatment Market Size study & Forecast, by Drug Type (Benzodiazepines, Nonbenzodiazepines, Antidepressants, and Other Drug Types) by Application (Insomnia, Sleep Apnea, Narcolepsy, Circadian disorders, and Other Applications) and Regional Analysis, 2022-2029

Global Sleep Disorders Treatment Market is valued approximately USD XX billion in 2021 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2022-2029. The sleep disorders treatment market refers to the industry that develops, produces, and markets various products and services that are used to diagnose and treat sleep disorders such as insomnia, sleep apnea, restless leg syndrome, and others. The market includes pharmaceutical drugs, medical devices, and behavioral therapies. The major driving factors for the Global Sleep Disorders Treatment Market are increasing prevalence of sleep disorders, growing aging population and increasing awareness about sleep disorders. Moreover, advancements in treatment options and favorable reimbursement policies of government are creating lucrative growth opportunity for the market over the forecast period 2022-2029.

The rising incidence of sleep disorders and the general increase in public knowledge of these conditions are factors in the market's expansion. Half of US adults report having insomnia once a month or more, according to Helsestart data on world insomnia numbers in 2022 and 2023. The West is the region most susceptible to insomnia, with about 59% of adults experiencing insomnia at some time. The same source also claimed that, among all nations, individuals in Japan, Taiwan, and Sweden struggle with insomnia the most. In the two years between 2021 and 2022, Norway had 67 more melatonin inquiries per 100,000 people than Sweden, making it the country with the most melatonin searches globally. However, the high cost of Sleep Disorders Treatment stifles market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global Sleep Disorders Treatment Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is the largest market for sleep disorders treatment due to the high prevalence of sleep disorders, favorable reimbursement policies, and the presence of major players in the region. The Asia-Pacific region is expected to witness significant growth in the sleep disorders treatment market due to the rising prevalence of sleep disorders, increasing healthcare expenditure, and the presence of a large patient pool.

Major market player included in this report are:
Takeda Pharmaceuticals USA Inc.
Vanda Pharmaceuticals Inc.
Merck & Co.
Mylan NV
Pfizer
Teva Pharmaceuticals USA Inc
Philips Healthcare
ResMed
Fisher & Paykel Healthcare
GlaxoSmithKline

Recent Developments in the Market:
In 2021, Philips launched its DreamStation 2, a continuous positive airway pressure (CPAP) device for sleep apnea treatment. The device is designed to be smaller and quieter than its predecessor, making it more comfortable for patients to use.
In 2021, ResMed acquired a digital therapeutics company, Propeller Health, to expand its offerings in respiratory and sleep therapy. Propeller Health's platform uses sensors and software to help patients manage their respiratory conditions.
Global Sleep Disorders Treatment Market Report Scope:
Historical Data 2019-2020-2021
Base Year for Estimation 2021
Forecast period 2022-2029
Report Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered Drug Type, Application, Region
Regional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and Drug Type offerings of key players.

The detailed segments and sub-segment of the market are explained below:
By Drug Type:
Benzodiazepines
Nonbenzodiazepines
Antidepressants
Other Drug Types
By Application:
Insomnia
Sleep Apnea
Narcolepsy
Circadian disorders
Other Applications

By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World

Companies Mentioned

Takeda Pharmaceuticals USA Inc.
Vanda Pharmaceuticals Inc.
Merck & Co.
Mylan NV
Pfizer
Teva Pharmaceuticals USA Inc
Philips Healthcare
ResMed
Fisher & Paykel Healthcare
GlaxoSmithKline

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.